IN THE HIGH COURT OF NEW ZEALAND AUCKLAND REGISTRY
I TE KŌTI MATUA O AOTEAROA TĀMAKI MAKAURAU ROHE
CIV-2020-404-801
[2023] NZHC 881
BETWEEN PBL SOLUTIONS LIMITED
First Plaintiff
AFT ORPHAN PHARMACEUTICALS LIMITED
Second PlaintiffAND
AFT PHARMACEUTICALS LIMITED
First Defendant
HARTLEY CAMPBELL ATKINSON
Second Defendant
Hearing: On the papers (submissions 30 March and 11 April 2023) Appearances:
JS Cooper KC, TJ Lindsay and CD Brownlee for the Plaintiffs AS Ross KC, MC Smith and Y Lee for the Defendants
Judgment:
21 April 2023
JUDGMENT OF FITZGERALD J
[As to application to file further evidence after closure of case]
This judgment was delivered by me on 21 April 2023 at 2.00pm, pursuant to Rule 11.5 of the High Court Rules.
Registrar/Deputy Registrar
Date……………
Solicitors: Lindsay & Francis, Auckland
Gilbert Walker, Auckland
To:J Cooper KC, Auckland A Ross KC, Auckland
PBL SOLUTIONS LTD v AFT PHARMACEUTICALS LTD [2023] NZHC 881 [21 April 2023]
Introduction
[1] In this proceeding, the plaintiffs claim that the first plaintiff and the first defendant were in a joint venture relationship for the purpose of developing and commercialising orphan drugs.1 PBL Solutions Ltd (PBL) says that the joint venture arrangement gave rise to fiduciary obligations owed by AFT Pharmaceuticals Ltd (AFT) to PBL. PBL further says that in breach of those fiduciary obligations, and/or in breach of contract, AFT effectively “stole” from the joint venture an opportunity relating to a drug called “Pascomer”, and has proceeded to develop and commercialise Pascomer for its own benefit.
[2] The primary relief sought by PBL is its proportionate share of an account of the future profits expected to be earned by AFT from Pascomer – valued and discounted to enable a “lump sum” payment to be made now.2 In the alternative (though very much advanced as a secondary claim), PBL seeks its proportionate share of future profits actually earned by AFT from Pascomer (as and when they are earned).3 The quantum claimed is substantial, though so too is the extent of dispute between the parties about that sum. PBL seeks an account of profits (based on its view as to the net present value of the Pascomer opportunity) of between US$53 million and US$67 million. Conversely, in addition to denying liability, AFT says that the net present value of Pascomer is virtually nil, or is indeed a negative figure.
[3] The claim is of some complexity, particularly in relation to quantum. The hearing took place over the period 31 October 2022 to 18 November 2022, and then a further two days of closing submissions on 8 and 9 December 2022.
[4] Part of the alleged value of the Pascomer opportunity turns on the likelihood of the drug receiving regulatory approval for marketing and sale in two key markets — the US and the European Union (the EU). Also relevant to that value is the timing of a competitor’s product (“Hyftor”, developed by Nobelpharma) receiving approval in those markets. This is because once an orphan drug is approved, it will
1 “Orphan…
Keep reading for free
Create a free CaseChat account to read PBL Solutions Limited v AFT Pharmaceuticals Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2023] NZHC 881
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.